Skip to main content
    X

    X4 Pharmaceuticals Inc (XFOR)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $2.64
    +0.19 (+7.76%)

    Market Cap: $242.91M

    Last updated: Oct 16, 2026 at 1:55 PM ET

    Earnings

    Performance (10Y)

    Beat Rate
    46%(16/35)
    Avg Surprise
    -9.63%
    Streak
    6 Q

    Upcoming Estimates

    Period ending Sep 30, 2026
    EPS Consensus$-0.19
    Range$-0.22 - $-0.16
    5 analysts
    EPS Revisions
    1
    0
    7d
    1
    0
    30d
    EPS Estimate DriftChange to current
    90d ago$-0.20+5.8%
    60d ago$-0.19+3.1%
    30d ago$-0.190.0%
    7d ago$-0.190.0%
    Current$-0.19
    Revenue Consensus
    $2M
    Range$2M - $3M
    5 analysts
    Period ending Dec 31, 2026
    EPS Consensus$-0.10
    Range$-0.22 - $-0.02
    5 analysts
    Revenue Consensus
    $8M
    Range$7M - $9M
    5 analysts
    PeriodReportedEst.SurpriseB/MYoY
    Dec 26EST
    		-$-0.10---
    Sep 26EST
    		-$-0.19---
    Jun 26
    Reported Aug 6
    		$-0.13$-0.19+31.58%Beat+96.3%
    Mar 26
    Reported May 6
    		$-0.16$-0.20+20.00%Beat-500.0%
    Dec 25
    Reported Mar 17
    		$-0.22$-0.35+36.69%Beat-10.0%
    Sep 25
    Reported Nov 5
    		$-0.69$-0.79+12.66%Beat+87.2%
    Jun 25
    Reported Aug 8
    		$-3.47$-4.34+20.05%Beat-63.7%
    Mar 25
    Reported May 1
    		$0.04N/A+101.07%Beat+115.4%
    Dec 24
    Reported Mar 25
    		$-0.20$-0.16-26.98%Miss+93.3%
    Sep 24
    Reported Nov 13
    		$-5.40$-5.16-4.65%Miss-1700.0%
    Jun 24
    Reported Aug 8
    		$-2.12$0.75-382.67%Miss+78.6%
    Mar 24
    Reported May 7
    		$-0.26$-0.16-62.50%Miss-62.5%
    Dec 23
    Reported Mar 21
    		$-3.00$-4.55+34.07%Beat+65.5%
    Sep 23
    Reported Nov 9
    		$-0.30N/A+93.01%Beat+96.2%
    Jun 23
    Reported Aug 10
    		$-9.90$-4.93-100.81%Miss+45.0%
    Mar 23
    Reported May 4
    		$-0.16$-0.22+27.27%Beat+99.3%
    Dec 22
    Reported Mar 21
    		$-8.70$-7.24-20.17%Miss-866.7%
    Sep 22
    Reported Nov 3
    		$-7.80$-9.53+18.15%Beat+65.8%
    Jun 22
    Reported Aug 4
    		$-18.00$-19.25+6.49%Beat+18.9%
    Mar 22
    Reported May 12
    		$-21.60$-18.53-16.57%Miss+44.6%
    Dec 21
    Reported Mar 17
    		$-0.90$-0.68-32.35%Miss+1.1%
    Sep 21
    Reported Nov 4
    		$-22.80$-21.30-7.04%Miss+12.6%
    Jun 21
    Reported Aug 3
    		$-22.20$-22.08-0.54%Miss+2.6%
    Mar 21
    Reported May 6
    		$-39.00$-25.76-51.40%Miss-6864.3%
    Dec 20
    Reported Mar 4
    		$-0.91$-0.90-1.11%Miss+95.4%
    Sep 20
    Reported Nov 5
    		$-26.10$-21.97-18.80%Miss+28.7%
    Jun 20
    Reported Jul 30
    		$-22.80$-21.54-5.85%Miss+25.5%
    Mar 20
    Reported May 7
    		$-0.56$-0.80+30.00%Beat+99.7%
    Dec 19
    Reported Mar 12
    		$-19.80$-25.65+22.81%Beat-405.1%
    Sep 19
    Reported Nov 7
    		$-36.60$-32.00-14.38%Miss-702.6%
    Jun 19
    Reported Aug 6
    		$-30.60$-29.10-5.15%Miss-500.0%
    Mar 19
    Reported May 15
    		$-200.10$-98.97-102.18%Miss-4406.8%
    Dec 18
    Reported Mar 11
    		$-3.92$-4.44+11.71%Beat+61.1%
    Sep 18
    Reported Nov 9
    		$-4.56$-3.88-17.53%Miss+81.3%
    Jun 18
    Reported Aug 13
    		$-5.10$-4.90-4.08%Miss-862.3%
    Mar 18
    Reported May 10
    		$-4.44$-6.24+28.85%Beat-788.0%
    Dec 17
    Reported Mar 9
    		$-10.08$-17.80+43.37%Beat-
    Sep 17
    Reported Nov 17
    		$-24.36N/AN/ABeat-
    Jun 17
    Reported Sep 20
    		$-0.53$0.00N/AMiss-
    Mar 17
    Reported May 4
    		$-0.50$0.00N/AMiss-

    Key Metrics

    Valuation
    P/E Ratio-2.20EV/EBITDAN/A
    Price/FCFN/AFCF YieldN/A
    Profitability
    Profit Margin0.00%Operating Margin-186.10%
    ROE-113.10%ROIC-38.05%
    Financial Health
    Debt/Equity0.49xInterest Coverage-10.11x
    Current Ratio11.30xQuick Ratio11.02x
    Trading Statistics
    Beta0.46Avg Volume938.14K
    52-Week High$4.8352-Week Low$2.43

    Technical Indicators Dashboard

    Moving Averages

    SMA 10$2.75
    SMA 20$2.94
    SMA 50$3.58
    SMA 200$3.85
    EMA 10$2.75
    EMA 20$2.95
    EMA 50$3.36
    EMA 200$3.77

    MACD

    Line: -0.27Signal: -0.26Hist: -0.00

    ADX

    ADX: 43.3+DI: 14.4-DI: 32.9

    Aroon & PSAR

    Aroon Up8.0
    Aroon Down96.0
    PSAR$2.94

    Bollinger Bands

    Upper Band$3.51
    Lower Band$2.37
    %B Position3898%(Upper)
    Band Width0.24

    RSI (14-Day)

    Neutral
    33.7

    Momentum Oscillators

    Stoch %K12.9
    Stoch %D11.5
    Williams %R-66.4
    ROC (10d)-6.7%
    Momentum-0.19
    CCI (20d)-113.4
    MFI (14d)20.0

    Volatility Measures

    ATR (14d)$0.19(7.2%)
    StdDev (20d)0.29
    Hist Vol64.2%(High)

    Volume Flow

    VWAP$2.59
    OBV215.2M
    AD Line8.8B
    CMF (20d)-0.143

    Volume Metrics

    Avg Vol (20d)951.5K
    Vol Ratio0.6x
    VWMA (20d)$2.99

    Pivot Points

    R3$2.64
    R2$2.60
    R1$2.52
    Pivot Point$2.48
    S1$2.40
    S2$2.36
    S3$2.28

    Advanced Oscillators

    TSI-42.99
    Ultimate Osc47.7
    KST-251.72

    Financial Data

    QuarterJun 2026Mar 2026Dec 2025Sep 2025Jun 2025Mar 2025Dec 2024Sep 2024Jun 2024Mar 2024Dec 2023Sep 2023
    Total Revenue$8.81M$2.71M$2.14M$1.96M$1.97M$28.81M$1.43M$560,000$563,000$0$3.06M$0
    Cost of Revenue$1.62M$598,000$364,000$351,000$326,000$4.72M$302,000$227,000$268,000$0$62,000$0
    Gross Profit$7.19M$2.11M$1.78M$1.61M$1.65M$24.09M$1.13M$333,000$295,000$0$-62,000$0
    Operating Expenses$23.58M$22.42M$25.90M$28.92M$27.88M$33.53M$36.85M$34.83M$-70,808,000$37.29M$25.20M$27.21M
    R&D$15.08M$15.45M$18.52M$17.34M$18.35M$18.51M$21.70M$19.17M$20.91M$19.85M$15.27M$19.08M
    SG&A$8.50M$6.97M$7.38M$11.59M$9.53M$15.02M$15.14M$15.66M$13.28M$17.43M$9.93M$8.13M
    Operating Income$-16,391,000$-20,306,000$-23,699,000$-27,509,000$-26,232,000$-9,443,000$-35,715,000$-34,500,000$71.10M$-37,289,000$-25,199,000$-27,214,000
    Interest Income$1.98M$2.10M$1.99M$901,000$665,000$1.02M$1.27M$1.87M$1.56M$1.07M$1.45M$1.39M
    Interest Expense$2.16M$2.13M$2.19M$2.26M$2.23M$2.20M$2.30M$2.41M$2.18M$1.87M$1.89M$1.63M
    Income Before Tax$-16,155,000$-20,241,000$-23,925,000$-29,845,000$-25,704,000$316,000$-39,563,000$-36,681,000$90.85M$-51,747,000$-19,097,000$-2,279,000
    Income Tax Expense$2,000$0$0$-30,000$37,000$34,000$258,000$15,000$18,000$19,000$33,000$26,000
    Net Income$-16,157,000$-20,241,000$-23,925,000$-29,815,000$-25,741,000$282,000$-39,821,000$-36,696,000$90.83M$-51,766,000$-19,130,000$-2,305,000
    EBITDA$-14,973,000$-19,989,000$-23,501,000$-28,266,000$-23,782,000$1.97M$-38,253,000$-35,871,000$91.66M$-50,877,000$-18,594,000$-1,929,000
    EBIT$-15,970,000$-20,212,000$-23,724,000$-28,489,000$-24,137,000$1.49M$-38,526,000$-36,138,000$91.46M$-50,939,000$-18,656,000$-2,033,000
    * Some calculated fields are derived from available data when not provided by source

    Related GNG Research

    No research available

    Be the first to write about XFOR

    News

    X4 sets October 29 investor day. MarketBeat cites USD 11.25 for X4 Pharmaceuticals stock

    X4 Pharmaceuticals has scheduled a virtual Investor Day for October 29, 2026, to discuss its mavorixafor program...

    ad-hoc-news.de•10/15/26•Bullish

    X4 Pharmaceuticals Secures New $150 Million Term Loan

    X4 Pharmaceuticals has secured a new senior secured term loan agreement for up to $150 million with K2 HealthVentures and other lenders. The initial $80 million tranche was used to repay a previous loan...

    The Globe and Mail•10/10/26•Neutral

    X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

    X4 Pharmaceuticals announced it will host a virtual Investor Day on Thursday, October 29, 2026, to discuss mavorixafor as a potential treatment for chronic neutropenia. The event will feature discussions with management...

    Yahoo! Finance Canada•10/9/26•Bullish

    X4 Pharmaceuticals (XFOR) pairs a new loan with an approximately $78.7M debt payoff.

    X4 Pharmaceuticals secured a senior secured term loan facility of up to $150 million from K2 HealthVentures. The first tranche of $80 million was funded on October 7, 2026...

    Stock Titan•10/9/26•Bullish

    X4 Pharmaceuticals to Host Virtual Investor Day on Thursday, October 29, 2026, Featuring Key Opinion Leaders

    X4 Pharmaceuticals announced it will host a virtual Investor Day on Thursday, October 29, 2026, to discuss mavorixafor as a potential treatment for chronic neutropenia. The event will feature company management...

    The Manila Times•10/9/26•Somewhat-Bullish

    XFOR Valuation and Fair Value

    P/E
    -2.2x
    P/B
    2.1x
    See GNG's fair value

    XFOR Profitability: Margins, ROIC and FCF

    Gross margin
    81.2%
    Operating margin
    -186.1%
    Net margin
    0.0%
    ROIC
    -38.1%
    ROE
    -113.1%
    FCF margin
    -700.1%

    XFOR Competitors

    CompanyTicker
    Lifecore Biomedical Inc.LFCR
    Rocket Pharmaceuticals IncRCKT
    SAB Biotherapeutics IncSABS
    Profound Medical CorpPROF
    Bicycle Therapeutics LtdBCYC
    TriSalus Life Sciences Inc.TLSI
    So-Young International IncSY
    Fate Therapeutics IncFATE

    Sector: Healthcare

    XFOR Analyst Ratings

    Consensus
    Buy
    Analysts
    5
    Strong Buy
    0
    Buy
    5
    Hold
    0
    Sell
    0
    Strong Sell
    0

    XFOR Bull Case vs Bear Case

    Bull case

    • XFOR beat EPS estimates in 75.0% of its last 8 reported quarters.
    • XFOR grew quarterly revenue 346.3% year over year.
    • 100.0% of XFOR's analyst ratings are Buy or Strong Buy.

    XFOR Earnings: Beat Rate and Next Report

    Beat rate
    6 of 8 quarters (75.0%)
    Average surprise
    23.8%
    EPS estimate (fiscal period ending Sep 30, 2026)
    $-0.19
    Estimate revisions (30 days, fiscal period ending Sep 30, 2026)
    1 up, 0 down

    Frequently Asked Questions About XFOR

    Does XFOR pay dividends?

    X4 Pharmaceuticals Inc (XFOR) does not currently pay a regular dividend.

    What is XFOR's market cap?

    X4 Pharmaceuticals Inc (XFOR) has a market capitalization of $242.91M with a current stock price of $2.64.

    Related stocks

    Sector: Healthcare

    All stocks starting with X

    Get full access to GNG Research

    Create a free account to access portfolio tracking, advanced tools, and more.

    Create Free AccountLog In